Story
Scribe Therapeutics Files for US Initial Public Offering on Nasdaq
Biotechnology company Scribe Therapeutics has taken the first official step toward becoming a publicly traded entity, filing a registration statement for an initial public offering (IPO) on the Nasdaq Global Market.
Filing Details
According to the public filing, the company plans to list its common stock under the proposed ticker symbol SCTX. The initial registration statement did not specify the number of shares to be offered or the expected price range, using placeholder values, which is common in early-stage IPO filings.
A consortium of investment banks will manage the offering. The underwriters listed in the filing include:
- Leerink Partners
- Goldman Sachs & Co. LLC
- Guggenheim Securities
- Wells Fargo Securities
AdPath to Public Markets
This filing marks a significant milestone for Scribe Therapeutics, which currently has no public market for its common stock. The successful completion of the IPO is contingent upon the company satisfying all of Nasdaq’s listing standards and favorable market conditions.
Investors will be watching for subsequent amendments to the filing, which will provide concrete financial details and the specific terms of the offering. The move signals the company's intent to raise capital from public markets to fund its future operations and research.